Opportunities in the C5 inhibitors market include developing next-gen biosimilars and biosuperiors to improve administration frequency and expand treatment indications for diseases like aHUS, SCD, MG, ...
Following 2 doses of OMS906, all patients achieved an increase in hemoglobin of ³ 4.0 g/dL, with a mean hemoglobin change from baseline of 4.75 g/dL (p < 0.001) Following 3 doses of OMS906, mean ...
Please provide your email address to receive an email when new articles are posted on . Kim’s hypothesis arises partially from studies that showed that C3, when introduced to synthetic neutrophils, ...
TSP-1 reduced C3 and C5 cleavage and formation of the membrane attack complex, attenuating complement-mediated injury in AAV models. Complement activation is a relevant driver in the pathomechanisms ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results